secwatch.observer — SEC 8-K summary
======================================

Issuer:     COGNITION THERAPEUTICS INC (CGTX)
CIK:        0001455365
Form:       8-K
Filed at:   2023-05-04T23:59:59+00:00
Accession:  0001104659-23-055999
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cognition Therapeutics Q1 net loss $6.2M; advances Alzheimer's and dry AMD trials
--------------------------------------------------------------------------------

- Net loss $6.2M ($0.21 per share) vs $3.8M ($0.17) in Q1 2022.
- Cash $38.8M; runway into H2 2024; $35M equity agreement with Lincoln Park Capital.
- Completed enrollment in Phase 2 SEQUEL (Alzheimer's); topline data expected Q2 2023.
- FDA cleared Phase 2 START (540 patients) for early AD and Phase 2 MAGNIFY for dry AMD.
- Hired John Doyle as CFO effective May 1, 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1455365/000110465923055999/0001104659-23-055999-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1455365/000110465923055999/tm2314531d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-055999

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer